<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-6-270</article-id><article-id pub-id-type="pmid">17125518</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-270</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic polymorphisms of <italic>MMP1</italic>, <italic>MMP3 </italic>and <italic>MMP7 </italic>gene promoter and risk of colorectal adenoma</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Li&#x000e8;vre</surname><given-names>Astrid</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>astrid-lievre@orange.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Milet</surname><given-names>Jacqueline</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>milet@vjf.inserm.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Carayol</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carayol@vjf.inserm.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Le Corre</surname><given-names>Delphine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>delphine.lecorre@univ-paris5.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Milan</surname><given-names>Chantal</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>chantal.milan@u-bourgogne.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Pariente</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>alex.pariente@wanadoo.fr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Nalet</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>bernard.nalet@ch-montelimar.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Lafon</surname><given-names>Jacques</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>jacques.lafon@ch-aix.fr</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Faivre</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>jean.faivre@chu-dijon.fr</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Bonithon-Kopp</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>bonithon@u-bourgogne.fr</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Olschwang</surname><given-names>Sylviane</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>olschwangs@marseille.fnclcc.fr</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Bonaiti-Pelli&#x000e9;</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>bonaiti@vjf.inserm.fr</email></contrib><contrib id="A13" corresp="yes" contrib-type="author"><name><surname>Laurent-Puig</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Pierre.laurent-puig@univ-paris5.fr</email></contrib><contrib id="A14" contrib-type="author"><collab>members of the ANGH group</collab><email>Pierre.laurent-puig@univ-paris5.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>INSERM U775 et Universit&#x000e9; Ren&#x000e9; Descartes, Paris, France</aff><aff id="I2"><label>2</label>INSERM, U535, Villejuif, France</aff><aff id="I3"><label>3</label>Universit&#x000e9; Paris-Sud, IFR69, Villejuif, France</aff><aff id="I4"><label>4</label>INSERM E106, Facult&#x000e9; de M&#x000e9;decine, Dijon, France</aff><aff id="I5"><label>5</label>Centre Hospitalier, Pau, France</aff><aff id="I6"><label>6</label>Centre Hospitalier, Mont&#x000e9;limar, France</aff><aff id="I7"><label>7</label>Centre Hospitalier, Aix-en-Provence, France</aff><aff id="I8"><label>8</label>INSERM U599, Institut Paoli Calmettes, Marseille, France</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>24</day><month>11</month><year>2006</year></pub-date><volume>6</volume><fpage>270</fpage><lpage>270</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/270"/><history><date date-type="received"><day>30</day><month>7</month><year>2006</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Li&#x000e8;vre et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Li&#x000e8;vre et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Li&#x000e8;vre Astrid astrid-lievre@orange.fr </dc:author><dc:title> Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Cancer 6(1): 270-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2006)6:1&#x0003c;270&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Matrix metalloproteinases (MMP) have been shown to play a role in colorectal cancer (CRC). More recently, <italic>MMP1</italic>, <italic>MMP3 </italic>and <italic>MMP7 </italic>functional gene promoter polymorphisms have been found to be associated with CRC occurrence and prognosis. To document the role of MMP polymorphisms in the early step of colorectal carcinogenesis, we investigated their association with colorectal adenoma risk in a case-control study comprising 295 patients with large adenomas (LA), 302 patients with small adenomas (SA) and 568 polyp-free (PF) controls.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients were genotyped using automated fragment analysis for <italic>MMP1 </italic>-1607 ins/del G and <italic>MMP3 </italic>-1612 ins/delA (<italic>MMP3.1</italic>) polymorphisms and allelic discrimination assay for <italic>MMP3 </italic>-709 A/G (<italic>MMP3.2</italic>) and <italic>MMP7 </italic>-181 A/G polymorphisms. Association between MMP genotypes and colorectal adenomas was first tested for each polymorphism separately and then for combined genotypes using the combination test. Adjustment on relevant variables and estimation of odds ratios were performed using unconditional logistic regression.</p></sec><sec><title>Results</title><p>No association was observed between the polymorphisms and LA when compared to PF or SA. When comparing SA to PF controls, analysis revealed a significant association between <italic>MMP3 </italic>-1612 ins/delA polymorphism and SA with an increased risk associated with the 6A/6A genotype (OR = 1.67, 95%CI: 1.20&#x02013;2.34). Using the combination test, the best association was found for <italic>MMP3.1</italic>-<italic>MMP1 </italic>(p = 0.001) with an OR of 1.88 (95%CI: 1.08&#x02013;3.28) for the combined genotype 2G/2G-6A/6A estimated by logistic regression.</p></sec><sec><title>Conclusion</title><p>These data show a relation between <italic>MMP1 </italic>-1607 ins/del G and <italic>MMP3 </italic>-1612 ins/delA combined polymorphisms and risk of SA, suggesting their potential role in the early steps of colorectal carcinogenesis.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Colorectal cancer (CRC) is one of the most common human malignancies with more than 300,000 cases both in the United States and in the European Union each year. The majority of the cases are sporadic and develop from a pre-malignant lesion, the adenomatous polyp [<xref ref-type="bibr" rid="B1">1</xref>]. Colonoscopic polypectomy has been proved to reduce significantly the incidence of colorectal cancer [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Therefore, the identification of factors associated with the development of colorectal adenoma represents a major goal in the prevention of colorectal cancer. Indeed, they could allow the selection of individuals at risk of CRC who may benefit from a screening by colonoscopy.</p><p>Matrix metalloproteinases (MMPs) are an important family of metal-dependant enzymes that are responsible for the degradation of extracellular matrix components. MMPs are involved in various physiologic processes, such as embryogenesis and tissue remodeling [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. They also play a key role in invasion and metastasis of tumor cells which require proteolysis of basal membranes and extracellular matrix [<xref ref-type="bibr" rid="B6">6</xref>]. For a long time, MMPs were considered to be important almost exclusively in these two steps of carcinogenesis. However, recent studies suggested that MMPs are involved in several other processes associated with cancer development. Indeed, they regulate tumor growth and apoptosis, they promote angiogenesis, loss of cell adhesion, invasion and metastasis. Finally, some of them are also required in immune responses to cancer [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The role of MMPs in CRC has been described [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Numerous, including MMP1, MMP3 and MMP7 are overexpressed in colorectal tumors [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. The expression of MMP7 was shown to correlate with Dukes' stage and increased metastatic potential [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] while MMP-1 expression was shown to be related to invasion, metastasis and prognosis [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Moran <italic>et al</italic>. demonstrated that MMP3 expression was significantly lower in CRC with high microsatellite instability which are known to have a better clinical outcome than CRC without microsatellite instability [<xref ref-type="bibr" rid="B17">17</xref>]. This observation suggests that MMP3 could be implicated in tumor invasion, lymph node involvement and metastatic spread in CRC. MMPs are overexpressed in a variety of premalignant tumor tissues, including colorectal adenoma [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>] and MMP7 has been shown to be important in the growth of early colonic adenomas and their transformation into invasive cancer [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>A functional single nucleotide polymorphism (SNP) has been reported in the <italic>MMP1 </italic>gene promoter that consists in a guanosine (G) insertion at position -1607. This SNP generates a new 5'-GGA-3' core recognition sequence for members of the Ets family of transcription factors [<xref ref-type="bibr" rid="B22">22</xref>]. <italic>In vitro</italic>, the homozygous 2G/2G genotype results in an increased transcription activity compared to the 1G/1G genotype. <italic>In vivo</italic>, an association was found between the 2G allele and MMP1 overexpression in ovarian cancer tissue [<xref ref-type="bibr" rid="B23">23</xref>]. The <italic>MMP1 </italic>2G/2G genotype was reported to be linked to an increased risk of CRC [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Indeed, the 2G allele was shown to favor invasion, metastasis and prognosis [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. A SNP corresponding to an insertion/deletion of an adenosine (A) at position -1612 of the <italic>MMP3 </italic>gene promoter was also described and shown to interfere with transcriptional activity [<xref ref-type="bibr" rid="B10">10</xref>]. In a case-control study, Hinoda <italic>et al</italic>. found that the frequency of the 6A allele was significantly higher in CRC patients than in controls, as the frequency of the 6A/6A genotype compared to the 5A/6A + 5A/5A genotypes [<xref ref-type="bibr" rid="B24">24</xref>]. In this study, <italic>MMP1 </italic>and <italic>MMP3 </italic>were in significant linkage desequilibrum and the most frequent haplotype 2G-6A was significantly increased in CRC patients compared to controls. Concerning the other <italic>MMP3 </italic>polymorphisms, four are in substantial linkage desequilibrum with the -1612 ins/del A (-1986 T/C, -1346 A/C, -376 G/C, and +802 A/G), except one (-709 A/G) which is not of proven functional importance [<xref ref-type="bibr" rid="B27">27</xref>]. In the MMP7 gene promoter region, two SNPs (-181 A/G and -153 C/T) have been shown to modify the gene transcription activity [<xref ref-type="bibr" rid="B28">28</xref>]. Recently, both SNPs have been associated with CRC susceptibility and the -181 G/G genotype was linked to distant metastasis [<xref ref-type="bibr" rid="B29">29</xref>]. These findings are in favor of the role of <italic>MMP1</italic>, <italic>MMP3 </italic>and <italic>MMP7 </italic>functional gene polymorphisms in colorectal carcinogenesis. They are localized in a MMP cluster of 400 kb at 11q21&#x02013;23 that counts 9 MMPs (MMP-1, 3, 7, 8, 10, 12, 13, 20, 27).</p><p>To explore whether <italic>MMP1</italic>, <italic>MMP3 </italic>and <italic>MMP7 </italic>gene promoter polymorphisms are involved in the early step of colorectal carcinogenesis, we investigated the relation between these polymorphisms and the risk of colorectal adenoma in a case-control study.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Selection of cases and controls</title><p>The GEADE study is a case-control and family study of patients with high-risk adenomas (larger than 9 mm). The data were obtained from 18 participating gastroenterology units of general hospitals in France (table <xref ref-type="table" rid="T3">3</xref>). From September 1995 to March 2000, 306 consecutive patients with newly diagnosed colorectal large adenoma (LA) were enrolled in the study. Subjects with history of cancer, familial adenomatous polyposis, established hereditary non-polyposis colorectal cancer and inflammatory bowel disease had been excluded. In order to be able to distinguish genetic factors involved in the occurrence of adenomas or in their growth, 307 cases with small adenomas (SA) (smaller than 0.5 cm) and 572 polyp-free (PF) controls (with normal colonoscopy) were enrolled in the same units. All patients and controls were Caucasian. Information on indication of colonoscopy, family history of CRC, and completeness of colonoscopy was also collected for all patients and controls. Controls (2 per case) were matched to LA cases by age, gender, and geographic area (five regions: Paris area, North-East, Centre, South-West and South-East, France) (table <xref ref-type="table" rid="T3">3</xref>). Patients with SA were relatively rare and could not be matched with LA cases. Blood specimens were obtained at the time of the colonoscopy and were kept only if adenoma was diagnosed after histological examination (for LA and SA cases). Twenty individuals could not be genotyped because biological material was not sufficient: 11 cases with LA, 5 cases with SA and 4 PF controls. The final sample was thus: 295 cases with LA, 302 cases with SA and 568 PF controls. A complete description of the patients sample is given in Cottet <italic>et al</italic>. [<xref ref-type="bibr" rid="B30">30</xref>]. All patients and controls gave their informed consent and the study was approved by an ethics committee for biomedical research (Le Kremlin-Bic&#x000ea;tre) and by the National Committee CNIL (Commission nationale de l'informatique et des libert&#x000e9;s).</p></sec><sec><title>MMP1, MMP3 and MMP7 genotyping</title><p>The <italic>MMP1 </italic>-1607 ins/del G, <italic>MMP3 </italic>-1612 ins/del A, <italic>MMP3 </italic>-709 A/G and <italic>MMP7 </italic>-181 A/G polymorphisms were named respectively <italic>MMP1</italic>, <italic>MMP3.1</italic>, <italic>MMP3.2 </italic>and <italic>MMP7 </italic>polymorphisms.<italic>MMP1 </italic>and <italic>MMP3.1 </italic>have been studied by genotyping lymphocyte DNA by multiplex PCR-based approach using the following primers: 5' [6FAM]-GCCCTCTTGAACTCACATGTTATG-3' and 5'-ACTTTCCTCCCCTTATGGATTCC-3' for <italic>MMP1</italic>, 5'-GTCCTCATATCAATGTGGCCAAA-3' and 5' [6FAM]-CGGCACCTGGCCTAAAGAC-3' for <italic>MMP3.1 </italic>polymorphism as previously described [<xref ref-type="bibr" rid="B31">31</xref>]. After amplification and dilution, fragments were separated on a ABI Prism 3700 DNA Genetic Analyzer (Applied Biosystems).</p><p>The <italic>MMP3.2 </italic>and <italic>MMP7 </italic>polymorphisms were studied by real-time PCR allelic discrimination assay on ABI 7900 HT Sequence Detection System (Applied Biosystems) as previously described [<xref ref-type="bibr" rid="B31">31</xref>]. For the <italic>MMP7 </italic>DNA amplification was performed with forward 5'-AGTCAATTTATGCAGCAGACAGAAA-3' and reverse 5'-GTGTTATTTTTCATTAACTAAAACGAGGA-3' primers and allelic discrimination was performed by the use of specific probes for each allele respectively labelled with fluorescent reporter dyes VIC and FAM: 5'ACAATGTATTTGTCTTTC-3' and 5'-CAATGTATTCGTCTTTC-3'. For the <italic>MMP3.2 </italic>polymorphism, a mix containing specific primers and fluorescent probes designed by Applied Biosystems (Taqman SNP Genotyping Assay, ID C_3047714_10) was used. Some QC blinded samples were distributed throughout the runs and genotyped for concordance of results and control samples without DNA samples were systematically included in each MMP genotyping plate.</p></sec><sec><title>Statistical analysis</title><p>Hardy-Weinberg proportions were tested for each polymorphism. Linkage disequilibrium (LD) between pairwise loci was estimated using the measure D' [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Association was first tested for each polymorphism separately. For each polymorphism, genotype-specific odds ratio (OR) and 95% confidence intervals (CI) were computed using unconditional logistic regression adjusted on matching factors and Wald test was used to assess the global effect of this SNP. The homozygous genotype for the more frequent allele among controls was set as the reference class. Homogeneity of allele frequencies within regions was previously tested. Tests of homogeneity and unconditional logistic regression were done using STATA.</p><p>The association was further examined using the combination test, a method developed by Jannot <italic>et al</italic>. [<xref ref-type="bibr" rid="B33">33</xref>] that allows for the analysis of all possible combinations of 1 to n tightly linked SNPs in order to test their association with the disease. For each SNP combination, the method computes a statistic test contrasting the genotypic (or haplotypic) distribution between cases and controls. Because all these tests are correlated (many of them are nested in each others, and the SNPs are likely to be in LD), a permutation procedure is implemented which displays a significance level adequately adjusted for multiple testing. In a second step, among the significantly associated combinations, the most parsimonious one can be identified by comparing nested combinations using chi2 tests.</p><p>With the 4 SNPs of the present study, a total of 15 SNP combination were tested (4 single SNP tests, 6 two-SNP tests, 4 three-SNP tests and 1 four-SNP test).</p><p>First, we used the FAMHAP12 software to apply this method by performing haplotypic tests [<xref ref-type="bibr" rid="B34">34</xref>]. Then, the COMBINTEST (Jannot, personal communication) was used to perform genotypic tests.</p><p>As the combination test does not yet allow an adjustment on confounders, when association was found significant, the combination was further tested using unconditional logistic regression and the risks associated with the different genotypes were estimated.</p></sec></sec><sec><title>Results</title><p>Table <xref ref-type="table" rid="T1">1</xref> shows some characteristics of the cases and controls. LA cases were slightly older than SA and PF controls, but there was no age difference between LA and SA patients, despite the absence of matching. The sex ratio (male/female) was similar in LA and PF because of matching, and slightly higher in LA than in SA patients.</p><p>The distribution of genotypes for the 4 polymorphisms was consistent with Hardy-Weinberg equilibrium (p = 0.65 for <italic>MMP1</italic>, p = 0.13 for <italic>MMP3.1</italic>, p = 0.36 for <italic>MMP3.2 </italic>and p = 0.10 for <italic>MMP7</italic>). As shown in table <xref ref-type="table" rid="T2">2</xref>, three of the four polymorphisms (<italic>MMP1</italic>, <italic>MMP3.1 </italic>and <italic>MMP3.2</italic>) were in LD but <italic>MMP7 </italic>was only in slight LD with <italic>MMP3.2 </italic>polymorphism (D' = 0.18) and was not found in LD with the other ones (D'&#x0003c; 0.05).</p><p>Some differences in allele frequencies were found between centres inside the regions defined for matching (the homogeneity of allele frequencies was rejected for 5 tests among the 20 ones performed). Although such differences might be due to chance, there might exist some kind of stratification within the 5 regions initially defined, as found for other polymorphisms [<xref ref-type="bibr" rid="B35">35</xref>]. Therefore, we adjusted analyses on smaller groups of centres to protect against spurious association due to possible remaining population admixture. Centres with too few participants were pooled with the geographically closest ones, which led to eleven categories (table <xref ref-type="table" rid="T3">3</xref>).</p><p>Results of analyses by single polymorphisms for LA vs PF, LA vs SA and SA vs PF are presented in table <xref ref-type="table" rid="T4">4</xref>. No association was observed between the polymorphisms and LA when compared to PF or SA. Conversely, a significant effect of <italic>MMP3.1 </italic>polymorphism was found when comparing SA to PF controls (p = 0.008, Wald test). The data suggest an opposite effect of 6A allele depending on whether one or two copies were present. Compared with the 5A/5A genotype, the 6A/6A variant genotype appeared associated with an increased risk of SA whereas 5A/6A was inversely associated but the ORs were not significantly different from 1.0. When we considered a recessive model, the genotype 6A/6A was this time clearly associated with a higher risk of SA compared with the genotypes 5A/5A and 5A/6A pooled together (OR = 1.67, 95%CI: 1.20&#x02013;2.34).</p><p>The haplotypic analysis with the combination test did not reveal any effect of the 4 polymorphisms on LA. When comparing SA vs PF, the test was globally significant after correction for multiple testing (p = 0.012). The combination of polymorphisms found associated with SA with the lowest p-value was <italic>MMP1-MMP3.1 </italic>(p = 0.001, uncorrected). This was the best combination as no other combinations of 1 or 2 SNP was significantly associated with SA (in particular, when <italic>MMP3.1 </italic>was considered alone, the p-value was 0.059). The genotypic analysis by the combination test provided quite similar results with a p-value of 0.03 after correction for multiple testing. The lowest p-value was found for the same combination <italic>MMP1-MMP3.1 </italic>(p = 0.003, uncorrected). The only difference was that <italic>MMP3.1 </italic>SNP alone was significantly associated with SA (p = 0.011). As in the haplotypic analysis, the comparison between statistics of MMP1-MMP3.1 and MMP3.1 combinations showed that the combination MMP3.1-MMP1 was the most significantly associated one.</p><p>An association between combined <italic>MMP1-MMP3.1 </italic>genotypes and SA was confirmed by logistic regression adjusted on centre (p = 0.002) (table <xref ref-type="table" rid="T5">5</xref>). The same opposite effect of 5A and 6A alleles shown in the SNP by SNP analyses was found for <italic>MMP3.1 </italic>but only for the carriers of genotype 2G/2G at the <italic>MMP1 </italic>locus.</p></sec><sec><title>Discussion</title><p>We investigated the role of <italic>MMP1</italic>, <italic>MMP3 </italic>and <italic>MMP7 </italic>promoter polymorphisms as colorectal cancer risk factors in a case-control study of cases with large adenomatous polyps (n = 295), versus small adenomatous polyps cases (n = 302) or PF controls (n = 568). These polymorphisms are known to modulate transcriptional activity, except for one (<italic>MMP3 </italic>-709 A/G) that is not of proven functional importance [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>The distribution of genotypes for the four polymorphisms was consistent with Hardy-Weinberg equilibrium. <italic>MMP1</italic>, <italic>MMP3.1 </italic>and <italic>MMP3.2 </italic>polymorphisms were found in LD, as previously in several studies, the <italic>MMP1 </italic>2G and <italic>MMP3.1 </italic>6A alleles as well as the <italic>MMP1 </italic>1G and <italic>MMP3.1 </italic>5A alleles were in LD with a D' coefficient between 0.50 and 0.92 according to the ethnic origin of the patients [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Concerning the <italic>MMP3.2 </italic>-709 A/G polymorphism, few data are available but one study reported a substantial LD between five <italic>MMP3 </italic>promoter polymorphisms, except for this one, which had a lower frequency of the minor allele (0.2 vs &#x0003e; 0.4 for the minor allele of the other polymorphisms) [<xref ref-type="bibr" rid="B27">27</xref>]. The <italic>MMP7 </italic>polymorphism was not found in LD with the others (D' &#x0003c; 0.05), which is consistent with the literature [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>In this case-control study, the <italic>MMP3.1 </italic>6A/6A genotype was significantly associated with an increased risk of SA when compared to PF controls (OR = 1.67, 95%CI: 1.20&#x02013;2.34, under a recessive model) while no association was observed between the MMP polymorphisms analyzed and LA when compared to PF or SA. Moreover, the combination test revealed a stronger effect of the <italic>MMP1-MMP3.1 </italic>2G/2G-6A/6A combined genotype. These results suggest that <italic>MMP1 </italic>polymorphism, which was not found to influence adenoma risk when taken alone, may have a role by interacting with the effect of <italic>MMP3.1</italic>. This finding underlines the importance of using the combination test for demonstrating combined effects of polymorphisms with little or no individual effect. Indeed, this test has been shown to be particularly powerful to detect the effect of polymorphisms when several polymorphisms interact with low marginal effect of each SNP and when one of the SNPs masks the expression of the other ones [<xref ref-type="bibr" rid="B33">33</xref>]</p><p>Our data suggest that the <italic>MMP3.1 </italic>polymorphism, and especially the <italic>MMP1-MMP3.1 </italic>2G/2G-6A/6A combined genotype might play a role at the earliest step of colorectal carcinogenesis by promoting the development of adenomas from normal colon epithelial cells. However, the following steps of colorectal carcinogenesis, in particular adenoma growth, could require the contribution of other factors. These factors could mask the effect of <italic>MMP1-MMP3.1 </italic>combined genotype and explain the absence of association when LA patients are compared to PF controls. However, these preliminary results must be taken with caution and have to be confirmed.</p><p>The <italic>MMP3.1 </italic>6A/6A genotype has already linked to the development of CRC. Indeed, its frequency was significantly higher in CRC patients than in controls when compared to the 5A/5A + 5A/6A genotypes in a case-control study [<xref ref-type="bibr" rid="B24">24</xref>]. These results are inconsistent with the hypothesis that the increased transcriptional level of <italic>MMP3 </italic>increases CRC susceptibility as the 6A/6A genotype is associated with the lowest transcriptional level [<xref ref-type="bibr" rid="B36">36</xref>]. One explanation may be that <italic>MMP3 </italic>is indirectly involved in the development of CRC [<xref ref-type="bibr" rid="B24">24</xref>]. The presence of an increased risk of adenomatous polyps of the colon in coronary atherosclerosis patients [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>] suggested that the association of the MMP3 6A/6A genotype and CRC is due to its link with an increased atherosclerosis risk [<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B41">41</xref>]. These speculations should obviously be taken with caution and the mechanisms underlying the potential involvement of <italic>MMP3.1 </italic>polymorphism in colorectal carcinogenesis remain to be clearly determined.</p><p>Different studies showed that some MMP, including MMP2, MMP7 and MMP9 are expressed in colorectal adenomas that are well established premalignant lesions of colorectal cancers [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B42">42</xref>], implying their role other than extracellular matrix destruction and metastasis in cancer development and progression. The expression of E1AF, an Ets family transcriptional factor that plays a role in the progression of CRC, has been shown to be associated with the expression of MMP1 and MMP7 in CRC tissues [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Moreover, E1AF has been reported to be a potent activator of cyclooxygenase-2 (COX-2) transcription [<xref ref-type="bibr" rid="B45">45</xref>] and it is established that COX-2 plays an important role in the early stages of colorectal carcinogenesis [<xref ref-type="bibr" rid="B46">46</xref>]. Finally, absence of MMP7 may result in a significant reduction in mean tumour number and average tumour diameter in Min (multiple intestinal neoplasia) mice deficient in this MMP [<xref ref-type="bibr" rid="B21">21</xref>]. These findings suggest that some MMP might contribute to early tumour development, especially in tumours of gastrointestinal tract. Although several studies analyzed the expression of different MMP in colorectal adenomas, none had investigated the role of functional MMP polymorphisms in the development of these premalignant lesions despite evidence of their implication in colorectal carcinogenesis.</p><p>In the present study, the <italic>MMP3.1 </italic>6A/6A genotype was significantly associated with an increased risk of SA. Moreover, the analysis of the effects of combined MMP genotypes by the means of the combination test allowed to find an indirect role of <italic>MMP1 </italic>polymorphism in this early step of colorectal carcinogenesis since a potentialisation of the effect of <italic>MMP3.1 </italic>polymorphism by this polymorphism has been shown. Such an effect would not have been identified if a separated analysis of each MMP genotype had been performed, underlining the relevance of the combination test.</p></sec><sec><title>Conclusion</title><p>These data show a relation between <italic>MMP1 </italic>-1607 ins/delG and <italic>MMP3 </italic>-1612 ins/delA combined polymorphisms and risk of colorectal SA, suggesting their potential role in the early steps of colorectal carcinogenesis.</p></sec><sec><title>Abbreviations</title><p>CRC; colorectal cancer</p><p>LA; large adenoma</p><p>MMP; matrix metalloproteinases</p><p>PF; polyp free</p><p>SA; small adenoma</p><p>SNP; single nucleotide polymorphism</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AL and DLC carried out the genotyping under the supervision of PLP. AP, BN, JL and the ANGH group participated to the inclusion of patients in the study and performed colonoscopies with polypectomy. SO carried out the DNA extraction. JM, JC and CBP performed the statistical analysis. CBP, CM, JF, CBK, SO, AP and JL participated in the design of the study and/or the management of the data. AL, CBP, JM and PLP drafted the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/270/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank all the following members of the ANGH Group for their participation in the GEADE study: TP. Berthel&#x000e9;my (Pau), P. Cassan (Vichy), M. Glikmanas (Meaux), G. Gatineau-Sailliant (Meaux), A. Courrier (Metz), D. Pillon (Bourg-en-Bresse), JP. Michalet (Beaune), JP. Latrive (Compi&#x000e8;gne), J. Blanchi (Le Mans), B. Bour (Le Mans), T. Morin (Tarbes), JL Legoux (Orl&#x000e9;ans), D Labarri&#x000e8;re (Orl&#x000e9;ans), B. Naudy (Toulon), D. Goldfain (Dreux), C. Bories (Beauvais), J. Andrieu (Le Chesnay), JL. Staub (Niort)</p><p>The study was supported by grants from the "Fondation de France", the French National Society of Gastroenterology, the "Association pour la Recherche sur le Cancer", the Regional Council of Burgundy and the French Ministry of Health (PHRC). The U775 unit is supported by the Ligue Nationale contre le Cancer.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>A genetic model for colorectal tumorigenesis</article-title><source>Cell</source><year>1990</year><volume>61</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">2188735</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(90)90186-I</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilbertsen</surname><given-names>VA</given-names></name></person-group><article-title>Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer</article-title><source>Cancer</source><year>1974</year><volume>34</volume><fpage>suppl:936</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197409)34:3+&#x0003c;936::AID-CNCR2820340722&#x0003e;3.0.CO;2-5</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winawer</surname><given-names>SJ</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Ho</surname><given-names>MN</given-names></name><name><surname>O'Brien</surname><given-names>MJ</given-names></name><name><surname>Gottlieb</surname><given-names>LS</given-names></name><name><surname>Sternberg</surname><given-names>SS</given-names></name><name><surname>Waye</surname><given-names>JD</given-names></name><name><surname>Schapiro</surname><given-names>M</given-names></name><name><surname>Bond</surname><given-names>JH</given-names></name><name><surname>Panish</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>1977</fpage><lpage>1981</lpage><pub-id pub-id-type="pmid">8247072</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199312303292701</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>AR</given-names></name><name><surname>Fingleton</surname><given-names>B</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Matrix metalloproteinases: biologic activity and clinical implications</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>1135</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">10694567</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visse</surname><given-names>R</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name></person-group><article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">12730128</pub-id><pub-id pub-id-type="doi">10.1161/01.RES.0000070112.80711.3D</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forget</surname><given-names>MA</given-names></name><name><surname>Desrosiers</surname><given-names>RR</given-names></name><name><surname>Beliveau</surname><given-names>R</given-names></name></person-group><article-title>Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis</article-title><source>Can J Physiol Pharmacol</source><year>1999</year><volume>77</volume><fpage>465</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">10535707</pub-id><pub-id pub-id-type="doi">10.1139/cjpp-77-7-465</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>New functions for the matrix metalloproteinases in cancer progression</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">11990853</pub-id><pub-id pub-id-type="doi">10.1038/nrc745</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leeman</surname><given-names>MF</given-names></name><name><surname>Curran</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>GI</given-names></name></person-group><article-title>New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression</article-title><source>J Pathol</source><year>2003</year><volume>201</volume><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">14648655</pub-id><pub-id pub-id-type="doi">10.1002/path.1466</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zucker</surname><given-names>S</given-names></name><name><surname>Vacirca</surname><given-names>J</given-names></name></person-group><article-title>Role of matrix metalloproteinases (MMPs) in colorectal cancer</article-title><source>Cancer Metastasis Rev</source><year>2004</year><volume>23</volume><fpage>101</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">15000152</pub-id><pub-id pub-id-type="doi">10.1023/A:1025867130437</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name></person-group><article-title>Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases</article-title><source>Matrix Biol</source><year>2000</year><volume>19</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">11102751</pub-id><pub-id pub-id-type="doi">10.1016/S0945-053X(00)00102-5</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>RE</given-names></name><name><surname>Leach</surname><given-names>IH</given-names></name><name><surname>Powe</surname><given-names>DG</given-names></name><name><surname>Clark</surname><given-names>IM</given-names></name><name><surname>Cawston</surname><given-names>TE</given-names></name><name><surname>Turner</surname><given-names>DR</given-names></name></person-group><article-title>Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours</article-title><source>Int J Cancer</source><year>1991</year><volume>49</volume><fpage>666</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">1657796</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Barnard</surname><given-names>GF</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Ueo</surname><given-names>H</given-names></name><name><surname>Akiyoshi</surname><given-names>T</given-names></name><name><surname>Sugimachi</surname><given-names>K</given-names></name></person-group><article-title>Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas</article-title><source>Cancer</source><year>1995</year><volume>75</volume><fpage>1516</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">7889484</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(19950315)75:6+&#x0003c;1516::AID-CNCR2820751522&#x0003e;3.0.CO;2-7</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><article-title>Suppression of matrilysin inhibits colon cancer cell invasion in vitro</article-title><source>Int J Cancer</source><year>1995</year><volume>61</volume><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">7705951</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiozawa</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Nakashima</surname><given-names>M</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name><name><surname>Sekine</surname><given-names>I</given-names></name></person-group><article-title>Expression of matrix metalloproteinase-1 in human colorectal carcinoma</article-title><source>Mod Pathol</source><year>2000</year><volume>13</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">11007031</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3880169</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>GI</given-names></name><name><surname>Duncan</surname><given-names>ME</given-names></name><name><surname>O'Neil</surname><given-names>P</given-names></name><name><surname>Melvin</surname><given-names>WT</given-names></name><name><surname>Fothergill</surname><given-names>JE</given-names></name></person-group><article-title>Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>461</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">8597958</pub-id><pub-id pub-id-type="doi">10.1038/nm0496&#x00026;ndash;461</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>EA</given-names></name><name><surname>Bergin</surname><given-names>FG</given-names></name><name><surname>Leaper</surname><given-names>DJ</given-names></name></person-group><article-title>Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging</article-title><source>Br J Surg</source><year>2000</year><volume>87</volume><fpage>1215</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">10971431</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2168.2000.01531.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Iniesta</surname><given-names>P</given-names></name><name><surname>de Juan</surname><given-names>C</given-names></name><name><surname>Gonzalez-Quevedo</surname><given-names>R</given-names></name><name><surname>Sanchez-Pernaute</surname><given-names>A</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Ramon y Cajal</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Balibrea</surname><given-names>JL</given-names></name><name><surname>Benito</surname><given-names>M</given-names></name></person-group><article-title>Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite instability sporadic colorectal tumors</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>3855</fpage><lpage>3860</lpage><pub-id pub-id-type="pmid">12097300</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Senota</surname><given-names>A</given-names></name><name><surname>Yoshimoto</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Yachi</surname><given-names>A</given-names></name></person-group><article-title>Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin</article-title><source>Biochem Biophys Res Commun</source><year>1994</year><volume>201</volume><fpage>657</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">8002999</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1994.1751</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name></person-group><article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas</article-title><source>Dis Colon Rectum</source><year>1996</year><volume>39</volume><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">8918435</pub-id><pub-id pub-id-type="doi">10.1007/BF02055119</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>N</given-names></name><name><surname>Ichikawa</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Momiyama</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Nagashima</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Mitsuhashi</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name></person-group><article-title>Matrilysin gene expression in sporadic and familial colorectal adenomas</article-title><source>Mol Carcinog</source><year>1997</year><volume>19</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">9290698</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2744(199708)19:4&#x0003c;225::AID-MC2&#x0003e;3.0.CO;2-B</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Heppner</surname><given-names>KJ</given-names></name><name><surname>Labosky</surname><given-names>PA</given-names></name><name><surname>Hogan</surname><given-names>BL</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>1402</fpage><lpage>1407</lpage><pub-id pub-id-type="pmid">9037065</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.4.1402</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>JL</given-names></name><name><surname>Mitchell</surname><given-names>TI</given-names></name><name><surname>Buttice</surname><given-names>G</given-names></name><name><surname>Meyers</surname><given-names>J</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Ozelius</surname><given-names>LJ</given-names></name><name><surname>Brinckerhoff</surname><given-names>CE</given-names></name></person-group><article-title>A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>5321</fpage><lpage>5325</lpage><pub-id pub-id-type="pmid">9850057</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanamori</surname><given-names>Y</given-names></name><name><surname>Matsushima</surname><given-names>M</given-names></name><name><surname>Minaguchi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Sagae</surname><given-names>S</given-names></name><name><surname>Kudo</surname><given-names>R</given-names></name><name><surname>Terakawa</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><article-title>Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4225</fpage><lpage>4227</lpage><pub-id pub-id-type="pmid">10485461</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Okayama</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>N</given-names></name><name><surname>Fujimura</surname><given-names>K</given-names></name><name><surname>Suehiro</surname><given-names>Y</given-names></name><name><surname>Hamanaka</surname><given-names>Y</given-names></name><name><surname>Hazama</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name></person-group><article-title>Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer</article-title><source>Int J Cancer</source><year>2002</year><volume>102</volume><fpage>526</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">12432557</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10750</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghilardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>ML</given-names></name><name><surname>Mangoni</surname><given-names>J</given-names></name><name><surname>Leviti</surname><given-names>S</given-names></name><name><surname>DeMonti</surname><given-names>M</given-names></name><name><surname>Guagnellini</surname><given-names>E</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group><article-title>Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>2344</fpage><lpage>2346</lpage><pub-id pub-id-type="pmid">11489811</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Lecomte</surname><given-names>T</given-names></name><name><surname>Ferraz</surname><given-names>JM</given-names></name><name><surname>Houllier</surname><given-names>AM</given-names></name><name><surname>Cugnenc</surname><given-names>PH</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name></person-group><article-title>Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">15701845</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beyzade</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>YK</given-names></name><name><surname>Day</surname><given-names>IN</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name></person-group><article-title>Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><fpage>2130</fpage><lpage>2137</lpage><pub-id pub-id-type="pmid">12821236</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00482-0</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jormsjo</surname><given-names>S</given-names></name><name><surname>Whatling</surname><given-names>C</given-names></name><name><surname>Walter</surname><given-names>DH</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name></person-group><article-title>Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2001</year><volume>21</volume><fpage>1834</fpage><lpage>1839</lpage><pub-id pub-id-type="pmid">11701474</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghilardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>ML</given-names></name><name><surname>Erario</surname><given-names>M</given-names></name><name><surname>Guagnellini</surname><given-names>E</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group><article-title>Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><fpage>1940</fpage><lpage>1942</lpage><pub-id pub-id-type="pmid">14578330</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2003.018911</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cottet</surname><given-names>V</given-names></name><name><surname>Pariente</surname><given-names>A</given-names></name><name><surname>Nalet</surname><given-names>B</given-names></name><name><surname>Lafon</surname><given-names>J</given-names></name><name><surname>Milan</surname><given-names>C</given-names></name><name><surname>Olschwang</surname><given-names>S</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name><name><surname>Bonaiti-Pellie</surname><given-names>C</given-names></name><name><surname>Bonithon-Kopp</surname><given-names>C</given-names></name></person-group><article-title>Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>24</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">16803608</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02966.x</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Gad</surname><given-names>S</given-names></name><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Maniere</surname><given-names>I</given-names></name><name><surname>Beauregard</surname><given-names>J</given-names></name><name><surname>Tregouet</surname><given-names>D</given-names></name><name><surname>Brasnu</surname><given-names>D</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><name><surname>Laccourreye</surname><given-names>O</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name></person-group><article-title>Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>2594</fpage><lpage>2599</lpage><pub-id pub-id-type="pmid">15102660</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-1116-03</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewontin</surname><given-names>RC</given-names></name></person-group><article-title>The Interaction of Selection and Linkage. I. General considerations : heterotic models</article-title><source>Genetics</source><year>1964</year><volume>49</volume><fpage>49</fpage><lpage>67</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jannot</surname><given-names>AS</given-names></name><name><surname>Essioux</surname><given-names>L</given-names></name><name><surname>Reese</surname><given-names>MG</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name></person-group><article-title>Improved use of SNP information to detect the role of genes</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">12916024</pub-id><pub-id pub-id-type="doi">10.1002/gepi.10256</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name></person-group><article-title>A powerful strategy to account for multiple testing in the context of haplotype analysis</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">15290652</pub-id><pub-id pub-id-type="doi">10.1086/424390</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lonjou</surname><given-names>C</given-names></name><name><surname>Clayton</surname><given-names>J</given-names></name><name><surname>Cambon-Thomsen</surname><given-names>A</given-names></name><name><surname>Raffoux</surname><given-names>C</given-names></name></person-group><article-title>HLA -A, -B, -DR haplotype frequencies in France--implications for recruitment of potential bone marrow donors</article-title><source>Transplantation</source><year>1995</year><volume>60</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">7652768</pub-id><pub-id pub-id-type="doi">10.1097/00007890-199508270-00013</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Kurkinen</surname><given-names>M</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Henney</surname><given-names>AM</given-names></name></person-group><article-title>Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>13055</fpage><lpage>13060</lpage><pub-id pub-id-type="pmid">8662692</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.22.13055</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>P</given-names></name><name><surname>Strong</surname><given-names>JP</given-names></name><name><surname>Johnson</surname><given-names>WD</given-names></name><name><surname>Pizzolato</surname><given-names>P</given-names></name><name><surname>Haenszel</surname><given-names>W</given-names></name></person-group><article-title>Atherosclerosis and polyps of the colon. Quantification of precursors of coronary heart disease and colon cancer</article-title><source>J Chronic Dis</source><year>1982</year><volume>35</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">7068807</pub-id><pub-id pub-id-type="doi">10.1016/0021-9681(82)90002-9</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stemmermann</surname><given-names>GN</given-names></name><name><surname>Heilbrun</surname><given-names>LK</given-names></name><name><surname>Nomura</surname><given-names>A</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name></person-group><article-title>Adenomatous polyps and atherosclerosis: an autopsy study of Japanese men in Hawaii</article-title><source>Int J Cancer</source><year>1986</year><volume>38</volume><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">3793259</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Mandalia</surname><given-names>S</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Henney</surname><given-names>AM</given-names></name></person-group><article-title>Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis</article-title><source>Br Heart J</source><year>1995</year><volume>73</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">7727178</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Luong</surname><given-names>LA</given-names></name><name><surname>Talmud</surname><given-names>PJ</given-names></name><name><surname>Frick</surname><given-names>MH</given-names></name><name><surname>Kesaniemi</surname><given-names>YA</given-names></name><name><surname>Pasternack</surname><given-names>A</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Syvanne</surname><given-names>M</given-names></name></person-group><article-title>The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial</article-title><source>Atherosclerosis</source><year>1998</year><volume>139</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">9699891</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(98)00053-7</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gnasso</surname><given-names>A</given-names></name><name><surname>Motti</surname><given-names>C</given-names></name><name><surname>Irace</surname><given-names>C</given-names></name><name><surname>Carallo</surname><given-names>C</given-names></name><name><surname>Liberatoscioli</surname><given-names>L</given-names></name><name><surname>Bernardini</surname><given-names>S</given-names></name><name><surname>Massoud</surname><given-names>R</given-names></name><name><surname>Mattioli</surname><given-names>PL</given-names></name><name><surname>Federici</surname><given-names>G</given-names></name><name><surname>Cortese</surname><given-names>C</given-names></name></person-group><article-title>Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1600</fpage><lpage>1605</lpage><pub-id pub-id-type="pmid">10845878</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>KJ</given-names></name><name><surname>Witty</surname><given-names>JP</given-names></name><name><surname>Rodgers</surname><given-names>WH</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis</article-title><source>Mol Carcinog</source><year>1994</year><volume>10</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">8068180</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Min</surname><given-names>Y</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><article-title>Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer</article-title><source>J Pathol</source><year>2003</year><volume>200</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">12898592</pub-id><pub-id pub-id-type="doi">10.1002/path.1387</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Mikami</surname><given-names>M</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><article-title>Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>892</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15695237</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi029</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>LR</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Subbaramaiah</surname><given-names>K</given-names></name><name><surname>Hassell</surname><given-names>JA</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><article-title>PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>20108</fpage><lpage>20115</lpage><pub-id pub-id-type="pmid">11274170</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M010692200</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>CS</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name></person-group><article-title>The role of cyclooxygenases in inflammation, cancer, and development</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>7908</fpage><lpage>7916</lpage><pub-id pub-id-type="pmid">10630643</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203286</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Large adenomas</td><td align="center">Small adenomas</td><td align="center">Polyp free controls</td></tr></thead><tbody><tr><td align="left">N</td><td align="center">295</td><td align="center">302</td><td align="center">568</td></tr><tr><td align="left">Age, mean (SD)</td><td align="center">62.3 (13.1)</td><td align="center">60.6 (12.1)</td><td align="center">60.7 (12.4)</td></tr><tr><td align="left">Sex ratio (male/female)</td><td align="center">1.68</td><td align="center">1.24</td><td align="center">1.52</td></tr></tbody></table><table-wrap-foot><p>SD; standard deviation</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Linkage disequilibrium (D') between pairwise polymorphisms</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphisms D' (p-value)</td><td align="left"><italic>MMP3.1</italic></td><td align="left"><italic>MMP7</italic></td><td align="left"><italic>MMP3.2</italic></td></tr></thead><tbody><tr><td align="left"><italic>MMP1</italic></td><td align="left">0.429 (&#x0003c; 0.001)</td><td align="left">0.016 (0.686)</td><td align="left">0.761 (&#x0003c; 0.001)</td></tr><tr><td align="left"><italic>MMP3.1</italic></td><td></td><td align="left">0.040 (0.231)</td><td align="left">0.946 (&#x0003c; 0.001)</td></tr><tr><td align="left"><italic>MMP7</italic></td><td></td><td></td><td align="left">0.185 (0.005)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Distribution of cases and controls in the different centres and groups of centres</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Region</td><td align="left">Centre</td><td align="center" colspan="2">Number of individuals by centre</td><td align="center" colspan="2">Number of individuals by group of centres</td></tr><tr><td></td><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td></td><td align="center">All cases</td><td align="center">Controls</td><td align="center">All cases</td><td align="center">Controls</td></tr></thead><tbody><tr><td align="left">Paris area</td><td align="left">Le Chesnay</td><td align="center">10</td><td align="center">15</td><td></td><td></td></tr><tr><td></td><td align="left">Meaux</td><td align="center">45</td><td align="center">32</td><td align="center">55</td><td align="center">47</td></tr><tr><td></td><td align="left">Orleans</td><td align="center">16</td><td align="center">7</td><td></td><td></td></tr><tr><td></td><td align="left">Le Mans</td><td align="center">49</td><td align="center">49</td><td align="center">65</td><td align="center">56</td></tr><tr><td></td><td align="left">Dreux</td><td align="center">12</td><td align="center">39</td><td align="center">12</td><td align="center">39</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">North-East</td><td align="left">Evreux</td><td align="center">25</td><td align="center">16</td><td></td><td></td></tr><tr><td></td><td align="left">Beauvais</td><td align="center">8</td><td align="center">19</td><td></td><td></td></tr><tr><td></td><td align="left">Soissons</td><td align="center">1</td><td align="center">1</td><td></td><td></td></tr><tr><td></td><td align="left">Compi&#x000e8;gne</td><td align="center">24</td><td align="center">16</td><td align="center">58</td><td align="center">51</td></tr><tr><td></td><td align="left">Metz</td><td align="center">45</td><td align="center">49</td><td align="center">45</td><td align="center">49</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Centre</td><td align="left">Vichy</td><td align="center">38</td><td align="center">2</td><td></td><td></td></tr><tr><td></td><td align="left">Bourg en Bresse</td><td align="center">76</td><td align="center">51</td><td align="center">114</td><td align="center">53</td></tr><tr><td></td><td align="left">Beaune</td><td align="center">37</td><td align="center">37</td><td align="center">37</td><td align="center">37</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">South-West</td><td align="left">Tarbes</td><td align="center">31</td><td align="center">29</td><td align="center">31</td><td align="center">29</td></tr><tr><td></td><td align="left">Pau</td><td align="center">67</td><td align="center">54</td><td align="center">67</td><td align="center">54</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">South-East</td><td align="left">Toulon</td><td align="center">10</td><td align="center">10</td><td></td><td></td></tr><tr><td></td><td align="left">Aix en Provence</td><td align="center">58</td><td align="center">61</td><td align="center">68</td><td align="center">71</td></tr><tr><td></td><td align="left">Mont&#x000e9;limar</td><td align="center">45</td><td align="center">36</td><td align="center">45</td><td align="center">36</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Association between genotypes of MMP and colorectal adenomas</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Large adenoma patients (LA)</td><td align="left">Polyp free controls (PF)</td><td align="left">Small adenoma patients (SA)</td><td align="left">LA vs PF</td><td></td><td align="left">LA vs SA</td><td></td><td align="left">SA vs PF</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td align="left">OR* (95%CI)</td><td align="left">P**</td><td align="left">OR* (95%CI)</td><td align="left">P**</td><td align="left">OR* (95%CI)</td><td align="left">P**</td></tr></thead><tbody><tr><td align="left"><bold><italic>MMP1</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">1G/1G</td><td align="left">81</td><td align="left">154</td><td align="left">81</td><td align="left">1</td><td></td><td align="left">1</td><td></td><td align="left">1</td><td></td></tr><tr><td align="left">1G/2G</td><td align="left">139</td><td align="left">285</td><td align="left">139</td><td align="left">0.94 (0.66&#x02013;1.33)</td><td></td><td align="left">1.04 (0.69&#x02013;1.56)</td><td></td><td align="left">0.96 (0.67&#x02013;1.37)</td><td></td></tr><tr><td align="left">2G/2G</td><td align="left">72</td><td align="left">122</td><td align="left">79</td><td align="left">1.18 (0.78&#x02013;1.78)</td><td align="left">0.491</td><td align="left">0.90 (0.56&#x02013;1.43)</td><td align="left">0.792</td><td align="left">1.22 (0.81&#x02013;1.84)</td><td align="left">0.431</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><bold><italic>MMP3.1</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">5A/5A</td><td align="left">70</td><td align="left">130</td><td align="left">68</td><td align="left">1</td><td></td><td align="left">1</td><td></td><td align="left">1</td><td></td></tr><tr><td align="left">5A/6A</td><td align="left">139</td><td align="left">291</td><td align="left">132</td><td align="left">0.87 (0.60&#x02013;1.25)</td><td></td><td align="left">1.10 (0.72&#x02013;1.69)</td><td></td><td align="left">0.85 (0.58&#x02013;1.24)</td><td></td></tr><tr><td align="left">6A/6A</td><td align="left">73</td><td align="left">126</td><td align="left">93</td><td align="left">1.11 (0.73&#x02013;1.69)</td><td align="left">0.391</td><td align="left">0.78 (0.48&#x02013;1.25)</td><td align="left">0.250</td><td align="left">1.50 (0.99&#x02013;2.28)</td><td align="left">0.008</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><bold><italic>MMP3.2</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">AA</td><td align="left">182</td><td align="left">358</td><td align="left">194</td><td align="left">1</td><td></td><td align="left">1</td><td></td><td align="left">1</td><td></td></tr><tr><td align="left">AG</td><td align="left">105</td><td align="left">187</td><td align="left">92</td><td align="left">1.10 (0.81&#x02013;1.50)</td><td></td><td align="left">1.20 (0.83&#x02013;1.73)</td><td></td><td align="left">0.87 (0.64&#x02013;1.20)</td><td></td></tr><tr><td align="left">GG</td><td align="left">7</td><td align="left">19</td><td align="left">16</td><td align="left">0.72 (0.29&#x02013;1.78)</td><td align="left">0.615</td><td align="left">0.49 (0.19&#x02013;1.27)</td><td align="left">0.175</td><td align="left">1.34 (0.65&#x02013;2.75)</td><td align="left">0.464</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><bold><italic>MMP7</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">AA</td><td align="left">92</td><td align="left">187</td><td align="left">99</td><td align="left">1</td><td></td><td align="left">1</td><td></td><td align="left">1</td><td></td></tr><tr><td align="left">AG</td><td align="left">138</td><td align="left">259</td><td align="left">136</td><td align="left">1.08 (0.77&#x02013;1.50)</td><td></td><td align="left">1.06 (0.72&#x02013;1.56)</td><td></td><td align="left">0.98 (0.70&#x02013;1.38)</td><td></td></tr><tr><td align="left">GG</td><td align="left">64</td><td align="left">119</td><td align="left">67</td><td align="left">1.17 (0.78&#x02013;1.77)</td><td align="left">0.742</td><td align="left">1.08 (0.67&#x02013;1.72)</td><td align="left">0.944</td><td align="left">1.14 (0.76&#x02013;1.71)</td><td align="left">0.746</td></tr></tbody></table><table-wrap-foot><p>* OR adjusted on age, sex, and group of centres</p><p>** P: p-value for the Wald test assessing the global effect of SNP, uncorrected for multiple testing</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Combined effect of <italic>MMP1 </italic>and <italic>MMP3.1 </italic>loci in small adenomas</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="2">Genotypes</td><td align="center">Polyp free (n)</td><td align="center">Small adenoma (n)</td><td align="center">OR* (95% CI)</td></tr><tr><td align="center"><italic>MMP1</italic></td><td align="center"><italic>MMP3.1</italic></td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="left">1G-1G</td><td align="center">5A-5A</td><td align="center">76</td><td align="center">47</td><td align="center">1</td></tr><tr><td align="left">1G-1G</td><td align="center">5A-6A</td><td align="center">58</td><td align="center">26</td><td align="center">0.77 (0.41&#x02013;1.43)</td></tr><tr><td align="left">1G-1G</td><td align="center">6A-6A</td><td align="center">19</td><td align="center">5</td><td align="center">0.37 (0.12&#x02013;1.12)</td></tr><tr><td align="left">1G-2G</td><td align="center">5A-5A</td><td align="center">46</td><td align="center">18</td><td align="center">0.68 (0.34&#x02013;1.38)</td></tr><tr><td align="left">1G-2G</td><td align="center">5A-6A</td><td align="center">174</td><td align="center">88</td><td align="center">0.83 (0.52&#x02013;1.33)</td></tr><tr><td align="left">1G-2G</td><td align="center">6A-6A</td><td align="center">56</td><td align="center">33</td><td align="center">1.13 (0.62&#x02013;2.04)</td></tr><tr><td align="left">2G-2G</td><td align="center">5A-5A</td><td align="center">8</td><td align="center">3</td><td align="center">0.63 (0.15&#x02013;2.62)</td></tr><tr><td align="left">2G-2G</td><td align="center">5A-6A</td><td align="center">59</td><td align="center">18</td><td align="center">0.45 (0.23&#x02013;0.89)</td></tr><tr><td align="left">2G-2G</td><td align="center">6A-6A</td><td align="center">51</td><td align="center">55</td><td align="center">1.88 (1.08&#x02013;3.28)</td></tr></tbody></table><table-wrap-foot><p>* OR adjusted on age, sex and group of centres</p></table-wrap-foot></table-wrap></sec></back></article> 